MKI67 and neoplasm: Cohort 1: ≥ 4 ALN OR 1–3 ALN with grade 3 and/or tumor size ≥ 5 cmCohort 2: 1–3 ALN and Ki-67 ≥ 20% (grade 1–2 and/or tumor size ≤ 5 cm)